Last reviewed · How we verify
Fractionated blood products transfusion
Fractionated blood products transfusion replaces or supplements specific blood components (plasma, platelets, red blood cells, clotting factors) to restore hemostasis and oxygen-carrying capacity in patients with deficiencies or massive hemorrhage.
Fractionated blood products transfusion replaces or supplements specific blood components (plasma, platelets, red blood cells, clotting factors) to restore hemostasis and oxygen-carrying capacity in patients with deficiencies or massive hemorrhage. Used for Massive hemorrhage and hemorrhagic shock, Coagulopathy secondary to trauma or surgery, Thrombocytopenia with active bleeding.
At a glance
| Generic name | Fractionated blood products transfusion |
|---|---|
| Sponsor | Direction Centrale du Service de Santé des Armées |
| Drug class | Blood product/Hemostatic agent |
| Modality | Small molecule |
| Therapeutic area | Hematology/Critical Care/Trauma |
| Phase | Phase 3 |
Mechanism of action
This therapeutic approach involves the transfusion of separated blood components rather than whole blood, allowing targeted replacement of deficient factors. It is used to correct coagulopathy, thrombocytopenia, anemia, and hypovolemia in trauma, surgery, and critical care settings. The fractionation allows precise dosing of needed components while minimizing volume overload and immune complications.
Approved indications
- Massive hemorrhage and hemorrhagic shock
- Coagulopathy secondary to trauma or surgery
- Thrombocytopenia with active bleeding
- Severe anemia requiring transfusion support
Common side effects
- Transfusion-related acute lung injury (TRALI)
- Febrile non-hemolytic transfusion reaction
- Allergic reaction
- Hemolytic transfusion reaction
- Transfusion-associated circulatory overload (TACO)
- Infection transmission risk
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: